T. Rowe Price Group

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

KoBold Metals specializes in global mineral exploration for battery materials. It combines geological expertise with advanced data analytics and machine learning to identify prospective cobalt sources, supporting the electric vehicle revolution.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.

MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.

Waymo is a self-driving technology company dedicated to improving mobility. Established from Google's labs in 2009, Waymo aims to make transportation safer and easier by developing advanced software and sensor technologies. The company achieved the world's first fully self-driven trip on public roads in 2015, using cars without steering wheels or pedals. Today, Waymo continues to refine its technology through extensive simulation testing and real-world driving across multiple cities.

Bluejay Therapeutics is a private biopharmaceutical company focused on developing curative treatments for infectious and liver diseases. Its initial program targets chronic hepatitis B, a widespread infection with unmet medical need, using two approaches: fully human IgG1 monoclonal antibodies against hepatitis B surface antigen and oral small-molecule inhibitors of HBsAg. The aim is to reduce viral surface antigen and restore adaptive immunity, potentially achieving a functional cure for HBV and enabling patients to regain immune control of infection. The company’s work also contemplates extending its approach to other viral liver diseases, including chronic hepatitis D.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Lambda specializes in deep-learning infrastructure, offering cloud technology, servers, and workstations pre-configured with common ML frameworks. This enables clients to simplify and accelerate the training and deployment of deep learning models, empowering AI engineers to construct, test, and deploy AI products efficiently and securely.

Lilac Solutions, Inc. is a mining technology company based in Oakland, California, specializing in lithium extraction technology. Founded in 2015, the company develops innovative solutions that utilize ion-exchange theory to absorb lithium from brine deposits. This technology includes ion exchange beads and continuous brine processing systems, which enable lithium producers to enhance project development, increase lithium recovery, and optimize operations. Lilac Solutions aims to support industries such as electric vehicles and renewable energy storage by providing methods that reduce both costs and environmental impact associated with lithium production.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Sortera Alloys manufactures low-cost, high-quality metal alloys for domestic manufacturing using its artificial intelligence technology. Sortera Alloys is a company based in Fort Wayne, Indiana, and was established in 2020.

ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Cleerly is a healthcare company developing digital care pathways to prevent heart attacks by establishing a new standard of care for coronary artery disease. The company combines clinical science with next-generation AI to deliver actionable insights across the heart care pathway, including a non-invasive platform that quantifies and characterizes plaque buildup in heart arteries. Its solutions aim to help healthcare providers identify at-risk patients early and support cost-effective prevention, ultimately improving cardiovascular outcomes and delivering value to the health system.

YuLife is a technology-driven insurance company founded in 2016 and headquartered in London. The company aims to inspire individuals and transform financial products into a force for good by integrating gamification and behavioral science into its offerings. YuLife provides life and medical insurance plans while promoting wellness by encouraging users to engage in health-related activities such as walking and meditation. Participants can earn rewards, including air miles, vouchers, and gift cards, which are designed to support their financial, emotional, and physical well-being. By focusing on healthy living, YuLife enables businesses to insure their employees while allowing individuals to reap the benefits of a healthier lifestyle.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Epirus, Inc. is a technology company based in Hawthorne, California, specializing in the design and development of advanced defense systems that utilize artificial intelligence and directed energy. Founded in 2018, the company focuses on creating solid-state, software-defined high-power microwave solutions aimed at countering unmanned aircraft systems and other asymmetric threats. Its flagship product, ELECTROMAGNETIC PULSE, serves as a counter-infrastructure solution that can simultaneously target multiple threats, effectively neutralizing drones and swarms. By integrating AI and machine learning with advanced electronics, Epirus enhances the detection and tracking of objects of interest, offering innovative capabilities in electronic warfare and power management for both defense and commercial sectors.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Founded by JB Straubel in Nevada, Redwood Materials specializes in recycling lithium-ion batteries and electronics. It develops processes to extract and refine key materials like lithium, nickel, cobalt, and copper, creating a circular supply chain for electric vehicles and energy storage systems. The company aims to reduce environmental impact and lower production costs by recycling end-of-life products.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

Founded in 2014, Jetti Resources specializes in hydrometallurgical technology for extracting metals from mineral ores. Its proprietary catalytic process is used to efficiently recover copper from low-grade primary sulfides like chalcopyrite, making it a cost-effective and environmentally responsible solution.

Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Tenaya Therapeutics is a preclinical-stage biotechnology company focused on developing therapies for heart disease and heart failure. It operates three product platforms: cellular regeneration, which aims to regenerate heart tissue by reprogramming cardiac fibroblasts into cardiomyocytes via delivery of proprietary transcription factors; gene therapy, which targets cardiac fibroblasts to deliver therapeutic payloads; and precision medicine, which enables personalized approaches to treat heart disease. Founded in 2016 and headquartered in South San Francisco, California, Tenaya seeks to address the underlying cellular pathologies of diseased myocardium with curative therapies that advance from discovery through development.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Rad Power Bikes LLC, based in Seattle, Washington, is North America's largest electric bike brand, incorporated in 2015. The company designs and manufactures electric bicycles suitable for both on and off-road use, offering feature-rich and affordable options tailored to individual needs. In addition to its bikes, Rad Power Bikes provides a range of accessories, including bags, fenders, racks, and safety products, as well as replacement parts like batteries and tires. Utilizing a direct-to-consumer sales model, the company has experienced rapid growth and aims to democratize electric biking, making energy-efficient transportation accessible and enjoyable for a wide audience. With a team of over 700 employees, Rad Power Bikes is committed to transforming the landscape of electric mobility.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Flexe, Inc. operates a cloud-based warehousing services marketplace that connects organizations needing additional warehousing and fulfillment services with those that have excess capacity. Founded in 2013 and headquartered in Seattle, the company specializes in omnichannel logistics, providing solutions for eCommerce fulfillment, retail distribution, same-day delivery, and network capacity. By integrating technology with an open logistics network, Flexe enables retailers, wholesalers, manufacturers, and logistics companies to optimize their operations, address inventory overflow, and streamline material handling. This approach allows clients to enhance their distribution networks by accessing affordable warehouse spaces, thereby maximizing revenue potential while maintaining operational efficiency.

Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.

Nuro is a technology company that develops autonomous driving technology and self-driving vehicles for local goods delivery. The company focuses on transforming local commerce by enabling merchants to deliver products directly to customers through autonomous delivery systems. Its autonomous driving platform is designed to work across vehicle types and to enable affordable, scalable fleet operations for goods transportation, reducing delivery times and offering a safer, contactless option for last-mile logistics.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Alignment Healthcare is a healthcare organization focused on enhancing the healthcare experience for seniors through innovative Medicare Advantage plans. The company offers customized care and services, emphasizing clinical coordination and risk management. By marketing these plans directly to consumers, Alignment Healthcare allows seniors to choose how they receive healthcare coverage and services each year. The organization integrates a technology platform with a clinical model, facilitating care delivery across various channels, including phone, online, and in-person at doctors' offices or senior homes. This approach aims to improve health outcomes and provide a more consumer-centric healthcare experience.

Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

Allbirds, founded in 2015 and based in San Francisco, is an apparel and fashion company specializing in eco-friendly footwear. It manufactures and sells a variety of shoe styles for men, women, and children, including wool runners, tree runners, and loungers, using premium natural materials. The company's mission is to create sustainable footwear that combines comfort, good design, and environmental responsibility. Allbirds operates through its own stores, retail partners, and an online platform, with a significant portion of its revenue coming from the United States market.

Convoy operates an online marketplace for digital freight network services. It connects shippers with local and regional trucks for moving goods efficiently, offering real-time tracking via its mobile app. Founded in 2015, Convoy aims to optimize the trucking industry by reducing waste and emissions.

Gusto is a SaaS company specializing in Human Capital Management. It offers a comprehensive suite of HR and payroll services, including payroll processing, benefits administration, time tracking, attendance management, and employee onboarding.

Framebridge, Inc. specializes in providing custom framing solutions for art and photographs through an online platform. Founded in 2013 and headquartered in Washington, D.C., the company simplifies the traditionally cumbersome and costly custom framing process. Customers can select from a curated range of contemporary frame styles, upload their images directly on the website, or send physical items in prepaid packaging for framing. Framebridge's expert team handcrafts each frame to meet the specific requirements of the customer, ensuring high-quality results. The finished products are then shipped directly to consumers, typically within days and ready for display. The company's pricing is transparent and based on the size of the framed item, starting at $39 and inclusive of free shipping. Framebridge aims to make custom framing accessible and efficient, enhancing the overall customer experience.

Checkr is a technology company that builds platforms for the background check industry. It provides screening services such as social security number trace, criminal record checks, driving records, verifications, drug tests, and credit checks, along with continuous monitoring and security infrastructure. The company offers an API and Checkr Connect IDV to integrate identity verification with background checks, enabling faster and more transparent hiring decisions. It serves multiple sectors, including financial services, retail and hospitality, healthcare, higher education, on-demand economy platforms, manufacturing, software and technology, and contact centers and peer-to-peer marketplaces. Founded in 2014, Checkr is headquartered in San Francisco.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

ShockWave Medical is a medical device company focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque in peripheral vascular, coronary vascular, and valvular diseases. The company markets lithoplasty catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee lesions, designed to modify calcium and improve vessel compliance before angioplasty or stent delivery. Its sonic pressure wave technology aims to limit injury to healthy tissue and facilitate procedures such as transcatheter coronary interventions and valve therapies. The business serves interventional cardiologists, vascular surgeons, and interventional radiologists through a direct sales force and distributors. It operates in the United States, Germany, the rest of Europe, and other international markets. Founded in 2009, ShockWave Medical is headquartered in Santa Clara, California.

Wheels Up is a membership-based private aviation company that specializes in on-demand flight services in the United States. By leveraging data and technology, it connects consumers with safety-vetted private aircraft, offering both programmatic and charter options. The company aims to reduce the upfront costs associated with private flying while providing flexibility, service, and safety to its members. Through its mobile app, users can easily book flights, manage accounts, and access ride-share opportunities. Additionally, members participate in the Wheels Down program, which enhances their travel experiences. Wheels Up operates a diverse fleet, utilizing owned, leased, and chartered aircraft to provide a wide range of global travel alternatives.

Evolve Vacation Rental Network, Inc. operates a marketing and booking platform that specializes in vacation rental management services for homeowners and guests. Founded in 2010 and based in Denver, Colorado, Evolve enables homeowners to effectively market and book their vacation properties online. The company offers a range of services, including professional property listings, marketing, guest communications, and local service provider connections. Evolve distinguishes itself by providing homeowners with enhanced performance, lower fees, and greater flexibility compared to traditional property management approaches. Its network of vetted local partners ensures comprehensive support, covering aspects like housekeeping and maintenance. This model aims to maximize rental income for property owners while delivering a seamless travel experience for guests.

Outset Medical is a medical technology company that develops innovative hemodialysis systems. Founded in 2003, it specializes in the Tablo dialysis machine, designed for both acute and chronic settings. The Tablo system features integrated water purification, on-demand dialysate production, software connectivity capabilities, and sensor-based automation.

ShockWave Medical is a medical device company focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque in peripheral vascular, coronary vascular, and valvular diseases. The company markets lithoplasty catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee lesions, designed to modify calcium and improve vessel compliance before angioplasty or stent delivery. Its sonic pressure wave technology aims to limit injury to healthy tissue and facilitate procedures such as transcatheter coronary interventions and valve therapies. The business serves interventional cardiologists, vascular surgeons, and interventional radiologists through a direct sales force and distributors. It operates in the United States, Germany, the rest of Europe, and other international markets. Founded in 2009, ShockWave Medical is headquartered in Santa Clara, California.

OfferUp operates an online platform facilitating local buying and selling of various items. Users can post items for sale within their networks, browse listings, and communicate with buyers/sellers directly through the app. The platform covers a wide range of product categories, from electronics to vehicles.

Magic Leap is an American startup specializing in Augmented Reality (AR) technology. The company develops proprietary wearable hardware that merges digital imagery with the real world, creating immersive AR experiences indistinguishable from reality. Their innovative Dynamic Digitized Lightfield Signal generates computer-generated 3D images that harmonize with human senses, enabling users to interact with digital devices in a visually cinematic manner. Magic Leap aims to redefine how users access screens and visualize data by combining inherent visual ability with mobile computing technology.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

OfferUp operates an online platform facilitating local buying and selling of various items. Users can post items for sale within their networks, browse listings, and communicate with buyers/sellers directly through the app. The platform covers a wide range of product categories, from electronics to vehicles.

Doximity is a cloud‑based digital platform that serves U.S. medical professionals. It offers a professional network and a suite of tools designed for collaboration, secure patient care coordination, virtual visits, career management, and access to the latest medical news and research. The platform is used by more than 70% of U.S. physicians across all specialties and practice areas.

Domo operates a cloud-based platform that digitally connects employees at all levels with real-time data and insights, enabling business management via smartphones.

Founded in 2007, Dropbox pioneered secure file sharing and collaboration. It offers cloud storage solutions for individuals and small to mid-sized businesses, with a focus on AI-powered universal search across unstructured data.

TrialPay, Inc. is a company that specializes in cross-platform monetization solutions, enabling merchants to connect with consumers through targeted promotions. Founded in 2006 and headquartered in Mountain View, California, with an additional office in Berlin, Germany, TrialPay offers a payment platform that allows customers to acquire items by trying or purchasing products from partner merchants. This system provides an alternative payment method, facilitating free trials and special offers through participation in deals from advertising partners. The company's diverse solutions cater to various industries, including software, gaming, online services, publishing, retail, and social networking, enhancing revenue growth and customer engagement for developers and merchants alike. As of March 2015, TrialPay operates as a subsidiary of Visa Inc.

Peixe Urbano is an online platform based in Florianópolis, Brazil, that allows users to discover and book deals across various sectors, including restaurants, beauty services, entertainment, and travel. Established in 2010, the platform connects consumers with local businesses, enhancing visibility and generating demand for their offerings. Peixe Urbano has gained recognition in the tech industry, having been awarded "Best International Startup of the Year" at the Crunchies Awards. By catering to individual preferences and localities, Peixe Urbano facilitates a seamless experience for users seeking discounts and promotions in multiple consumer service categories.

Zynga Inc., established in 2007, is a leading global developer, publisher, and operator of social games. The company's portfolio spans over 6 billion downloads across 175 countries, featuring popular franchises like FarmVille, Words With Friends, and Zynga Poker. Zynga's games are played on mobile platforms (iOS, Android) and social networking sites, with revenue generated through game downloads, in-game purchases, and advertising services. The company's headquarters are in San Francisco, California, with additional locations in North America, Europe, and Asia.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development and commercialization of innovative therapeutics for thrombosis, hematologic disorders, and inflammation. Founded in 2003, Portola's lead product, Andexxa, serves as an antidote for patients treated with rivaroxaban and apixaban. The company's portfolio also includes Bevyxxa, an oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical illnesses. Additionally, Portola is developing investigational therapies such as cerdulatinib, a dual inhibitor targeting spleen tyrosine kinase and Janus kinases for hematologic cancers, and various Syk inhibitors for chronic inflammatory diseases. Portola collaborates with several major pharmaceutical companies to enhance its research and development efforts. As of July 2020, Portola operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development and commercialization of innovative therapeutics for thrombosis, hematologic disorders, and inflammation. Founded in 2003, Portola's lead product, Andexxa, serves as an antidote for patients treated with rivaroxaban and apixaban. The company's portfolio also includes Bevyxxa, an oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical illnesses. Additionally, Portola is developing investigational therapies such as cerdulatinib, a dual inhibitor targeting spleen tyrosine kinase and Janus kinases for hematologic cancers, and various Syk inhibitors for chronic inflammatory diseases. Portola collaborates with several major pharmaceutical companies to enhance its research and development efforts. As of July 2020, Portola operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Terabeam is an American company that designs and manufactures free-space optical transceivers for internet access in downtown areas. Terabeam was founded in 1997 and is located in Kirkland, Washington. As of August 29, 2008, the company operates as subsidiary of Renaissance Electronics & Communications LLC.